WO2021145830A1 - Pharmaceutical compositions comprising mesalamine and relevant excipients in the treatment of ulcerative colitis - Google Patents
Pharmaceutical compositions comprising mesalamine and relevant excipients in the treatment of ulcerative colitis Download PDFInfo
- Publication number
- WO2021145830A1 WO2021145830A1 PCT/TR2020/050029 TR2020050029W WO2021145830A1 WO 2021145830 A1 WO2021145830 A1 WO 2021145830A1 TR 2020050029 W TR2020050029 W TR 2020050029W WO 2021145830 A1 WO2021145830 A1 WO 2021145830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mesalamine
- tank
- enema
- packaging
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Definitions
- the present invention relates to the preperation of pharmaceutical compositions comprising mesalamine in the treatment of ulcerative collitis, having an improved manufacturing process with superior packaging.
- Mesalamine has a chemical name as 5-Amino-2-hydroxybenzoic acid and its chemical structure is shown in the Figure I.
- Mesalamine has molecular weight of 153.135 g/mol, it appears as odorless white to pinkish crystals or purplish-tan powder.
- Mesalamine also known as mesalazine or 5 -amino salicylic acid (5-ASA) is a medication used to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
- IBD inflammatory bowel disease
- Inflammatory bowel disease is an umbrella term for two conditions (Crohn’s disease and ulcerative colitis) that are characterized by chronic inflammation of the gastrointestinal (GI) tract.
- GI gastrointestinal
- Crohn's disease is an inflammatory bowel disease that causes inflammation of digestive tract, which can lead to abdominal pain, fatigue, severe diarrhea, weight loss and malnutrition. Crohn's disease can be both painful and debilitating for IBD patients. Although there's no known cure for Crohn's disease, therapies can greatly reduce its signs and symptoms.
- Ulcerative colitis is one of inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers in digestive tract. Ulcerative colitis causes irritation, inflammation, and ulcers in the lining of your large intestine and rectum. Types of ulcerative colitis are ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis and acute severe ulcerative colitis.
- IBD inflammatory bowel disease
- liquid dosage form requires consideration of the physical, chemical, and biologic characteristics of all of the excipients and pharmaceutical ingredients to be used in fabricating the product.
- the drug and consisting pharmaceutical materials must be compatible with each other to produce a product that is stable, attractive, safe and easy to manage.
- Parameters such as pH, solubility, viscosity, osmolarity, dissolution and microbial limits are critical for developing liquid drugs. Excipients should be selected according to these parameters and also properties of active ingredient.
- EP0765664 relates to a pharmaceutical composition
- a pharmaceutical composition comprises an aqueous thixotropic suspension containing mesalazine and comprising usual excipients.
- US 2018/0140619 relates to a pharmaceutical enema composition
- a pharmaceutical enema composition comprises non-ionic block copolymer or mixture of polymers consisting of polyethylene glycol and polypropylene glycol blocks, phospholipid, corticosteroid, and water that is used for treating inflammatory bowel disease.
- US 2017/0000727 relates to an enema composition, comprises mesalazine granules suitable for reconstitution into enema, and enema bottle comprising one-way valve.
- the present invention relates to the preparation of pharmaceutical enema composition comprising mesalamine and an antioxidant agent, relevant excipients using beneficial process with an enema packaging system for treating inflammatory bowel disease.
- the present invention relates to the preparation of pharmaceutical enema composition comprising mesalamine, an antioxidant agent and relevant excipients using nitrogen application processing with an enema packaging system consisting primary and secondary packaging for treating inflammatory bowel disease.
- the present invention relates to the preparation of pharmaceutical enema composition comprising mesalamine, an antioxidant agent and relevant excipients, wherein packaging system consisting primer and seconder packaging and nitrogen gase is applied to reduce oxygen level below 2 ppm in the drug product in all manufacturing process.
- packaging system consisting primer and seconder packaging and nitrogen gase is applied to reduce oxygen level below 2 ppm in the drug product in all manufacturing process.
- the present invention relates to the preparation of enema pharmaceutical compositions comprising mesalamine and relevant excipients, wherein nitrogen gas is applied during manufacturing process.
- the present invention relates to the preparation of pharmaceutical enema composition
- pharmaceutical enema composition comprising a) mesalamine and, b) at least an antioxidant agent and relevant excipients,
- Nitrogen gas is used during all manufacturing process to remove free oxygen from product which results in maximum oxygen level as below 2 ppm in the drug product, and enema packaging system is consisted primary and secondary packaging.
- the present invention relates to the preparation of pharmaceutical enema composition
- pharmaceutical enema composition comprising a) mesalamine and, b) Potassium Metabisulphite as an antioxidant agent, using nitrogen gas during manufacturing to remove free oxygen from product which results in maximum oxygen level as below 2 ppm in the drug product with an enema packaging system consisting primary and secondary packaging for treating inflammatory bowel disease.
- the present invention relates to the preparation of enema pharmaceutical compositions comprising mesalamine and relevant excipients, wherein process including beneficial process with an enema packaging system consisting primary and secondary packaging.
- the present invention relates to the preparation of enema pharmaceutical compositions comprising mesalamine and relevant excipients, wherein process including nitrogen application processing with an enema packaging system consisting primary and secondary packaging.
- the present invention provides a pharmaceutical composition comprising mesalamine for the treatment of inflammatory bowel disease, wherein the composition including antioxidant agent such as Potassium Metabisulphite. pH, solubility, viscosity, osmolarity, density and microbial limits are critical physico chemical parameters to be checked while developping formula for for rectal enema. It is of utmost importance to use the excipients in a balanced way to obtain the optimum product for rectal enema.
- antioxidant agent such as Potassium Metabisulphite. pH, solubility, viscosity, osmolarity, density and microbial limits are critical physico chemical parameters to be checked while developping formula for for rectal enema. It is of utmost importance to use the excipients in a balanced way to obtain the optimum product for rectal enema.
- API solubility is vital for enema compositions.
- Relevant excipients should be selected in the formulations according to API solubility properties.
- pH agents are used for pH adjustment in the enema composition. pH agents can be selected from the group, but not limited to, sodium hydroxide, hydrochloric acid, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium acetate and the equivalent potassium salt and other materials known to one of ordinary skill in the art, and the mixtures thereof.
- Suspending agents and gelling agents are critical for viscosity in a formulation. These excipients should be selected to adjust viscosity value.
- microbial limits One of the most sensitive issues of enema formulation is microbial limits. Adjusting microbial limits is very critical for enema formulations.
- Production conditions are very affective for manufacturing process and final product stability.
- Production line should be designed in such a way which ensure minimum exposure of Mesalamine to atmospheric air and light.
- Mesalamine is unstable in the presence of air and direct light, resulting oxidation and light- catalyzed degradation of the drug product.
- Mesalamine is very sensitive to light and atmospheric air. Because of this, packaging material should be designed in a way to avoid transfer of atmospheric air & light to drug product. Primary and secondary packaging is needed for sensitive active ingredients such as mesalamine.
- Mesalamine API is susceptible to degradation. As a result of the degredation, the color of pharmaceutical enema changes from white to brown and thus increases the impurity.
- Nitrogen gase application is very helpful to remove free dissolved oxygen from water and thus prevent oxidative degradation of mesalamine API. Nitrogen gase should be applied to manufacturing process before addition of API to the process to have minimum interaction between free oxygen & API.
- Secondary packaging machine is equipped with with suitable equipment to spray nitrogen gas during packaging operation.
- Seconder packaging has advantageous to have a hermetically insulation from atmospheric air & moisture to primary pack containing drug product.
- the present invention relates to a manufacturing process for mesalamine enema comprising two parts. First part is until primer packaging, second part is seconder packaging. Nitrogen gase is appliedy in all manufacturing process.
- Oxygen gase level should be under 2 ppm in the drug product throughout the manufacturing process till packed in primary packaging material. Measurement of free dissolved oxygen gas level is crucial at all manufacturing steps. This level has been proven critical to prevent oxidative degredation of pharmaceutical drug product.
- the new formulations may be packed in Polyethylene corrogated enema bottles containing 4g mesalamine in 60 mL suspension.
- Primary Enema package comprises of polyethylene corrugated bottle capped with Canula and again packed in a secondary pack.
- the present invention relates to packaged individual, or "single-use", enemas for the treatment of inflammatory bowel disease (IBD).
- the present invention comprises an effective and stable dosage suspension of 5-ASA, as the active ingredient.
- the present invention relates to a mesalamine containing suspension in an minimum oxygen- containing aqueous medium, prepared by nitrogen purge and foam removed by vacuum techniques.
- Secondary packaging Filled Primary packs are brought to make Supra kind of packaging on a separate machine.
- Packaging material is APET/PE 500-50 pm unprinted Strip Foil.
- Nitrogen flushing unit is attached with secondary packaging machine also. Before sealing of pack, Nitrogen is flushed to remove entrapped air in the secondary pack.
- Example 1 Mesalamine (4 g/60mL) Rectal Suspension Manufacturing Procedure for enema composition comprising Mesalamine (4 g/60mL) Rectal Suspension;
- Disodium EDTA and Mesalamine adding to tank A containing water with Oxygen level below 2 ppm.
- Effective amount of a drug or pharmacologically active agent means an amount of the drug or agent that is nontoxic and sufficient to provide the desired effect, e.g., inflammatory bowel disease.
- treatment means any treatment of a disease or condition in a subject, such as a mammal, including: 1) preventing or protecting against the disease or condition, that is, causing the clinical symptoms not to develop; 2) inhibiting the disease or condition, that is, arresting or suppressing the development of clinical symptoms; and/or 3) relieving the disease or condition that is, causing the regression of clinical symptoms.
- the present invention provides methods for treatment of inflammatory bowel disease.
- “Inflammatory bowel disease,” as used herein, refers to a number of chronic inflammatory diseases including Crohn's disease, gastroduodenal Crohn's disease, Crohn's (granulomatous) colitis, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Beliefs disease, microscopic colitis, ulcerative proctitis, proctosigmoiditis, jejunoileitis, left-sided colitis, pancolitis, ileocolitis, ileitis, and indeterminate colitis. Crohn's disease and ulcerative colitis are the two most common forms of inflammatory bowel disease.
- Inflammatory bowel disease is an autoimmune disease of the digestive system. Crohn's disease may be localized to any portion of the gastrointestinal tract, including the terminal ileum, and may impact all cell types of the gastrointestinal tract. Ulcerative colitis is localized to the colon and rectum, and affects cells of the mucosa only.
- Drugs administered in the rectum has a faster action than the oral route and also have higher bioavailability. It is an effective route than oral route because it avoids first pass effect caused by upper gastrointestinal tract digestive processes. Clinical studies have shown that rectal mesalamine preparations in the form of enema is more effective than oral mesalamine preparations, particularly in inflammatory bowel disease.
- the present invention is prepared to packaged individual or single-use, enemas for the treatment of inflammatory bowel disease.
- antioxidants such as Potassium Metabisulphite in the pharmaceutical composition prevents oxidation of mesalamine.
- the free dissolved oxygen is removed by using nitrogen gas and thus the oxygen degradation of the product is prevented.
- the present invention provides pharmaceutical formulations comprising more stable pharmaceutical composition was obtained by using specific primary and secondary packaging materials during the shelf life.
- the present invention provides stable mesalamine pharmaceutical composition where oxygen level is under 2 ppm.
- the present invention provides pharmaceutical formulations comprising mesalamine and relevant excipients for a rectal suspension characterized by i) An exclusive and beneficial manufacturing process, ii) Stable formulation,
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the preparation of pharmaceutical compositions comprising mesalamine and an antioxidant agent in the treatment of ulcerative collitis, having an improved manufacturing process with superior packaging. Packaging system consisting of primer and seconder packaging and nitrogen gase is applied to reduce oxygen level below 2 ppm in the drug product. Preferably, the composition comprises Potassium Metabisulphite as antioxidant agent.
Description
PHARMACEUTICAL COMPOSITIONS COMPRISING MESALAMINE AND RELEVANT EXCIPIENTS IN THE TREATMENT OF ULCERATIVE COLITIS
Field of invention
The present invention relates to the preperation of pharmaceutical compositions comprising mesalamine in the treatment of ulcerative collitis, having an improved manufacturing process with superior packaging.
Background of the invention
Mesalamine has a chemical name as 5-Amino-2-hydroxybenzoic acid and its chemical structure is shown in the Figure I. Mesalamine has molecular weight of 153.135 g/mol, it appears as odorless white to pinkish crystals or purplish-tan powder.
Figure 1
Mesalamine, also known as mesalazine or 5 -amino salicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
Inflammatory bowel disease is an umbrella term for two conditions (Crohn’s disease and ulcerative colitis) that are characterized by chronic inflammation of the gastrointestinal (GI) tract.
Crohn's disease is an inflammatory bowel disease that causes inflammation of digestive tract, which can lead to abdominal pain, fatigue, severe diarrhea, weight loss and malnutrition. Crohn's disease can be both painful and debilitating for IBD patients. Although there's no known cure for Crohn's disease, therapies can greatly reduce its signs and symptoms.
Ulcerative colitis is one of inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers in digestive tract. Ulcerative colitis causes irritation, inflammation, and ulcers in the lining of your large intestine and rectum. Types of ulcerative colitis are ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis and acute severe ulcerative colitis.
The proper design / formulation of a liquid dosage form requires consideration of the physical, chemical, and biologic characteristics of all of the excipients and pharmaceutical ingredients to be used in fabricating the product. The drug and consisting pharmaceutical
materials must be compatible with each other to produce a product that is stable, attractive, safe and easy to manage.
Parameters such as pH, solubility, viscosity, osmolarity, dissolution and microbial limits are critical for developing liquid drugs. Excipients should be selected according to these parameters and also properties of active ingredient.
After 34 weeks treatment with mesalamine enema on ulcerative colitis patients, it was found to induce a high percentage of complete remission in patients who did not respond to / could not tolerate sulfasalazine / oral or rectal glucocorticoid therapy. This study was performed according to (Wendy L. Biddle and Philip B. Miner, Jr, Long-term use of mesalamine enemas to induce remission in ulcerative colitis, Gastroenterology, 1990)
EP0765664 relates to a pharmaceutical composition comprises an aqueous thixotropic suspension containing mesalazine and comprising usual excipients.
US 2018/0140619 relates to a pharmaceutical enema composition comprises non-ionic block copolymer or mixture of polymers consisting of polyethylene glycol and polypropylene glycol blocks, phospholipid, corticosteroid, and water that is used for treating inflammatory bowel disease.
US 2017/0000727 relates to an enema composition, comprises mesalazine granules suitable for reconstitution into enema, and enema bottle comprising one-way valve.
Summary of the invention
The present invention relates to the preparation of pharmaceutical enema composition comprising mesalamine and an antioxidant agent, relevant excipients using beneficial process with an enema packaging system for treating inflammatory bowel disease.
The present invention relates to the preparation of pharmaceutical enema composition comprising mesalamine, an antioxidant agent and relevant excipients using nitrogen application processing with an enema packaging system consisting primary and secondary packaging for treating inflammatory bowel disease.
The present invention relates to the preparation of pharmaceutical enema composition comprising mesalamine, an antioxidant agent and relevant excipients, wherein packaging system consisting primer and seconder packaging and nitrogen gase is applied to reduce oxygen level below 2 ppm in the drug product in all manufacturing process.
Detailed description of the invention
The present invention relates to the preparation of enema pharmaceutical compositions comprising mesalamine and relevant excipients, wherein nitrogen gas is applied during manufacturing process.
The present invention relates to the preparation of pharmaceutical enema composition comprising a) mesalamine and, b) at least an antioxidant agent and relevant excipients,
Nitrogen gas is used during all manufacturing process to remove free oxygen from product which results in maximum oxygen level as below 2 ppm in the drug product, and enema packaging system is consisted primary and secondary packaging.
The present invention relates to the preparation of pharmaceutical enema composition comprising a) mesalamine and, b) Potassium Metabisulphite as an antioxidant agent, using nitrogen gas during manufacturing to remove free oxygen from product which results in maximum oxygen level as below 2 ppm in the drug product with an enema packaging system consisting primary and secondary packaging for treating inflammatory bowel disease.
The present invention relates to the preparation of enema pharmaceutical compositions comprising mesalamine and relevant excipients, wherein process including beneficial process with an enema packaging system consisting primary and secondary packaging.
The present invention relates to the preparation of enema pharmaceutical compositions comprising mesalamine and relevant excipients, wherein process including nitrogen application processing with an enema packaging system consisting primary and secondary packaging.
The present invention provides a pharmaceutical composition comprising mesalamine for the treatment of inflammatory bowel disease, wherein the composition including antioxidant agent such as Potassium Metabisulphite. pH, solubility, viscosity, osmolarity, density and microbial limits are critical physico chemical parameters to be checked while developping formula for for rectal enema. It is of utmost importance to use the excipients in a balanced way to obtain the optimum product for rectal enema.
API solubility is vital for enema compositions. Relevant excipients should be selected in the formulations according to API solubility properties.
pH agents are used for pH adjustment in the enema composition. pH agents can be selected from the group, but not limited to, sodium hydroxide, hydrochloric acid, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium acetate and the equivalent potassium salt and other materials known to one of ordinary skill in the art, and the mixtures thereof.
Suspending agents and gelling agents are critical for viscosity in a formulation. These excipients should be selected to adjust viscosity value.
One of the most sensitive issues of enema formulation is microbial limits. Adjusting microbial limits is very critical for enema formulations.
Production conditions are very affective for manufacturing process and final product stability. Production line should be designed in such a way which ensure minimum exposure of Mesalamine to atmospheric air and light.
Mesalamine is unstable in the presence of air and direct light, resulting oxidation and light- catalyzed degradation of the drug product.
Mesalamine is very sensitive to light and atmospheric air. Because of this, packaging material should be designed in a way to avoid transfer of atmospheric air & light to drug product. Primary and secondary packaging is needed for sensitive active ingredients such as mesalamine.
Mesalamine API is susceptible to degradation. As a result of the degredation, the color of pharmaceutical enema changes from white to brown and thus increases the impurity.
In this process, water is used in suspension preparation and water contains free dissolved oxygen. Mesalamine API is prone to oxidative degradation. Free dissolved oxygen causes oxidation of Mesalmine which turns color of API to brown.
Nitrogen gase application is very helpful to remove free dissolved oxygen from water and thus prevent oxidative degradation of mesalamine API. Nitrogen gase should be applied to manufacturing process before addition of API to the process to have minimum interaction between free oxygen & API.
Secondary packaging machine is equipped with with suitable equipment to spray nitrogen gas during packaging operation. Seconder packaging has advantageous to have a hermetically insulation from atmospheric air & moisture to primary pack containing drug product.
The present invention relates to a manufacturing process for mesalamine enema comprising two parts. First part is until primer packaging, second part is seconder packaging. Nitrogen gase is appliedy in all manufacturing process.
Oxygen gase level should be under 2 ppm in the drug product throughout the manufacturing process till packed in primary packaging material. Measurement of free dissolved oxygen gas
level is crucial at all manufacturing steps. This level has been proven critical to prevent oxidative degredation of pharmaceutical drug product.
The new formulations may be packed in Polyethylene corrogated enema bottles containing 4g mesalamine in 60 mL suspension. Primary Enema package comprises of polyethylene corrugated bottle capped with Canula and again packed in a secondary pack.
The present invention relates to packaged individual, or "single-use", enemas for the treatment of inflammatory bowel disease (IBD). The present invention comprises an effective and stable dosage suspension of 5-ASA, as the active ingredient.
The present invention relates to a mesalamine containing suspension in an minimum oxygen- containing aqueous medium, prepared by nitrogen purge and foam removed by vacuum techniques.
Primary packaging: The finished product is then filled in corrugated PE bottles flushed with Nitrogen before filling. After filling and before capping again Nitrogen is flushed to ensure least amount of free oxygen in the product.
Secondary packaging: Filled Primary packs are brought to make Supra kind of packaging on a separate machine. Packaging material is APET/PE 500-50 pm unprinted Strip Foil. Nitrogen flushing unit is attached with secondary packaging machine also. Before sealing of pack, Nitrogen is flushed to remove entrapped air in the secondary pack.
Example 1: Mesalamine (4 g/60mL) Rectal Suspension
Manufacturing Procedure for enema composition comprising Mesalamine (4 g/60mL) Rectal Suspension;
1. Disodium EDTA and Mesalamine adding to tank A containing water with Oxygen level below 2 ppm.
2. Xanthan gum adding to tank B containing water.
3. Carbopol adding to tank B.
4. Mixture of tank B adding to tank A. (Oxygen level maximum 2ppm)
5. Sodium benzoate and potassium metabisulphite adding to tank C containing water.
6. Mixture of tank C adding to tank A. (Oxygen level maximum 2ppm )
7. Potassium acetate for pH adjusting.
8. Volume make up and final mixing. (Oxygen level maximum 2ppm)
9. Filling product in primary pack.
“Effective” amount of a drug or pharmacologically active agent means an amount of the drug or agent that is nontoxic and sufficient to provide the desired effect, e.g., inflammatory bowel disease.
The term "treatment" or "treating" means any treatment of a disease or condition in a subject, such as a mammal, including: 1) preventing or protecting against the disease or condition, that is, causing the clinical symptoms not to develop; 2) inhibiting the disease or condition, that is, arresting or suppressing the development of clinical symptoms; and/or 3) relieving the disease or condition that is, causing the regression of clinical symptoms.
The present invention provides methods for treatment of inflammatory bowel disease. “Inflammatory bowel disease,” as used herein, refers to a number of chronic inflammatory diseases including Crohn's disease, gastroduodenal Crohn's disease, Crohn's (granulomatous) colitis, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Beliefs disease, microscopic colitis, ulcerative proctitis, proctosigmoiditis, jejunoileitis, left-sided colitis, pancolitis, ileocolitis, ileitis, and indeterminate colitis. Crohn's disease and ulcerative colitis are the two most common forms of inflammatory bowel disease. Inflammatory bowel disease is an autoimmune disease of the digestive system. Crohn's disease may be localized to any portion of the gastrointestinal tract, including the terminal ileum, and may impact all cell types of the gastrointestinal tract. Ulcerative colitis is localized to the colon and rectum, and affects cells of the mucosa only.
Advantages
Drugs administered in the rectum has a faster action than the oral route and also have higher bioavailability. It is an effective route than oral route because it avoids first pass effect caused by upper gastrointestinal tract digestive processes. Clinical studies have shown that rectal mesalamine preparations in the form of enema is more effective than oral mesalamine preparations, particularly in inflammatory bowel disease.
The present invention is prepared to packaged individual or single-use, enemas for the treatment of inflammatory bowel disease.
The use of antioxidants such as Potassium Metabisulphite in the pharmaceutical composition prevents oxidation of mesalamine.
During production and filling, the free dissolved oxygen is removed by using nitrogen gas and thus the oxygen degradation of the product is prevented.
The present invention provides pharmaceutical formulations comprising more stable pharmaceutical composition was obtained by using specific primary and secondary packaging materials during the shelf life.
The present invention provides stable mesalamine pharmaceutical composition where oxygen level is under 2 ppm.
The present invention provides pharmaceutical formulations comprising mesalamine and relevant excipients for a rectal suspension characterized by i) An exclusive and beneficial manufacturing process, ii) Stable formulation,
Table 1: Comparative stability data for Mesalamin rectal suspension of Reference and Test product (primer and secondary packaging)
N/A: Not available ND: Not detected
Claims
1. A pharmaceutical enema formulation comprising mesalamine, an antioxidant agent and relevant excipients, wherein packaging system consisting of primer and seconder packaging and nitrogen gase is applied to reduce oxygen level below 2 ppm in the drug product.
2. A pharmaceutical composition according to claim 1, wherein the composition comprises Potassium Metabisulphite as antioxidant agent.
3. A pharmaceutical enema composition according to claim 1, wherein nitrogen gase is applied during all manufacturing process.
4. A pharmaceutical enema composition according to claim 1 wherein primary package is corrugated PE bottle.
5. A mesalamine enema formulation comprising according to any preceding claims, comprising the steps of; a. Disodium EDTA and Mesalamine adding to tank A containing water with Oxygen level below 2 ppm. b. Xantham gum adding to tank B containing water. c. Carbopol adding to tank B. Mixture of tank B adding to tank A. (Oxygen level maximum 2ppm) d. Sodium benzoate and potassium metabisulphite adding to tank C containing water. e. Mixture of tank C adding to tank A. (Oxygen level maximum 2ppm) f. Potassium acetate for pH adjusting. g. Volume make up and final mixing. (Oxygen level maximum 2ppm) h. Filling product in primary pack. i. Secondary packaging
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/050029 WO2021145830A1 (en) | 2020-01-16 | 2020-01-16 | Pharmaceutical compositions comprising mesalamine and relevant excipients in the treatment of ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/050029 WO2021145830A1 (en) | 2020-01-16 | 2020-01-16 | Pharmaceutical compositions comprising mesalamine and relevant excipients in the treatment of ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021145830A1 true WO2021145830A1 (en) | 2021-07-22 |
Family
ID=76863926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2020/050029 WO2021145830A1 (en) | 2020-01-16 | 2020-01-16 | Pharmaceutical compositions comprising mesalamine and relevant excipients in the treatment of ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021145830A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114668730A (en) * | 2022-04-20 | 2022-06-28 | 苏州中化药品工业有限公司 | Enema for treating ulcerative colitis and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657900A (en) * | 1983-09-27 | 1987-04-14 | Rowell Laboratories | Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method |
| US4664256A (en) * | 1983-09-06 | 1987-05-12 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
| US20100087537A1 (en) * | 2007-01-29 | 2010-04-08 | Alaven Pharmaceutical Llc | Reduced irritant enema for the treatment of inflammatory bowel disease (ibd) |
-
2020
- 2020-01-16 WO PCT/TR2020/050029 patent/WO2021145830A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664256A (en) * | 1983-09-06 | 1987-05-12 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
| US4657900A (en) * | 1983-09-27 | 1987-04-14 | Rowell Laboratories | Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method |
| US20100087537A1 (en) * | 2007-01-29 | 2010-04-08 | Alaven Pharmaceutical Llc | Reduced irritant enema for the treatment of inflammatory bowel disease (ibd) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114668730A (en) * | 2022-04-20 | 2022-06-28 | 苏州中化药品工业有限公司 | Enema for treating ulcerative colitis and preparation method thereof |
| CN114668730B (en) * | 2022-04-20 | 2023-04-07 | 苏州中化药品工业有限公司 | Enema for treating ulcerative colitis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2564476B2 (en) | Basic drug solution for softgel filling or two-piece encapsulation or tablet manufacturing | |
| TWI231759B (en) | Olopatadine formulations for topical administration | |
| JP4199306B2 (en) | Aqueous foamable composition | |
| US5916590A (en) | Soft gelatin pharmaceutical dosage form | |
| NO169155B (en) | PROCEDURE FOR THE PREPARATION OF IBUPROPHEN SUBSTANTIAL COPIES OF SOFT GELATIN | |
| US20240139132A1 (en) | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | |
| DK2387389T3 (en) | Composition for oral transmucosal administration of analgesic or antispasmodic molecules | |
| CA3004028A1 (en) | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | |
| CA2841358A1 (en) | Pharmaceutical compositions for rectal administration | |
| JP5850518B2 (en) | Polymeric cyclic nitroxide radical compound treatment for inflammation of ulcerative gastrointestinal tract | |
| WO2021145830A1 (en) | Pharmaceutical compositions comprising mesalamine and relevant excipients in the treatment of ulcerative colitis | |
| JP2003518036A (en) | Oxcarbazepine-containing suspension | |
| WO2005123133A1 (en) | A process for preparing ibuprofen soft gelatin capsules | |
| EP1033988B1 (en) | Parenteral formulations comprising 10-hydroxy-10,11-tetrahydrocarbamazepine, water and glucose | |
| EP3251676A1 (en) | Enema for rectal application | |
| TR2022010549T2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING MESALAMIN AND RELATED AUXILIARIES IN THE TREATMENT OF ULCERATIVE COLITIS | |
| JP7335256B2 (en) | Pharmaceutical formulation of emulsion of simethicone and loperamide | |
| US11464733B2 (en) | Enema for rectal application | |
| KR100606621B1 (en) | Aqueous ecabet sodium solution preparation | |
| ES2738652T3 (en) | Compositions of midazolam for oral administration in the treatment of seizures to obtain rapid onset of action | |
| Leese | Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss | |
| Rahić et al. | Compounded omeprazole suspension-stable or not? | |
| WO2021229278A1 (en) | Concentrated liquid non-steroidal antiandrogen solution and method for preparing the solution | |
| US20150202149A1 (en) | Pharmaceutical compositions of mesalamine suppositories | |
| US20150238451A1 (en) | Pharmaceutical compositions of diclofenac or salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20913377 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20913377 Country of ref document: EP Kind code of ref document: A1 |